

1 **Antibody longevity and cross-neutralizing activity following SARS-CoV-2 wave 1 and**

2 **B.1.1.7 infections**

3

4 Liane Dupont,<sup>1\*</sup> Luke B. Snell,<sup>2\*</sup> Carl Graham,<sup>1\*</sup> Jeffrey Seow,<sup>1</sup> Blair Merrick,<sup>2</sup> Thomas  
5 Lechmere,<sup>1</sup> Sadie R. Hallett,<sup>1</sup> Themoula Charalampous,<sup>2</sup> Adela Alcolea-Medina,<sup>2</sup> Isabella  
6 Huettner,<sup>1</sup> Thomas J. A. Maguire,<sup>1</sup> Sam Acors,<sup>1</sup> Nathalia Almeida,<sup>1</sup> Daniel Cox,<sup>1</sup> Ruth E.  
7 Dickenson,<sup>1</sup> Rui Pedro Galao,<sup>1</sup> Jose M. Jimenez-Guardeño,<sup>1</sup> Neophytos Kouphou,<sup>1</sup> Marie  
8 Jose Lista,<sup>1</sup> Suzanne Pickering,<sup>1</sup> Ana Maria Ortega-Prieto,<sup>1</sup> Harry Wilson,<sup>1</sup> Helena  
9 Winstone,<sup>1</sup> Cassandra Fairhead,<sup>2</sup> Jia Su,<sup>2</sup> Gaia Nebbia,<sup>2</sup> Rahul Batra,<sup>2</sup> Stuart Neil,<sup>1</sup> Manu  
10 Shankar-Hari,<sup>1</sup> Jonathan D. Edgeworth,<sup>2</sup> Michael H. Malim,<sup>1</sup> Katie J. Doores<sup>1#</sup>

11

12 <sup>1</sup>Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's  
13 College London, London, UK.

14 <sup>2</sup>Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases,  
15 Guy's and St Thomas' NHS Foundation Trust, London, UK.

16

17 \* These authors contributed equally

18 # To whom correspondence should be addressed: [katie.doores@kcl.ac.uk](mailto:katie.doores@kcl.ac.uk)

19

20

21 **Abstract:**

22 As SARS-CoV-2 variants continue to emerge globally, a major challenge for COVID-19  
23 vaccination is the generation of a durable antibody response with cross-neutralizing activity  
24 against both current and newly emerging viral variants. Cross-neutralizing activity against  
25 major variants of concern (B.1.1.7, P.1 and B.1.351) has been observed following  
26 vaccination, albeit at a reduced potency, but whether vaccines based on the Spike  
27 glycoprotein of these viral variants will produce a superior cross-neutralizing antibody  
28 response has not been fully investigated. Here, we used sera from individuals infected in  
29 wave 1 in the UK to study the long-term cross-neutralization up to 10 months post onset of  
30 symptoms (POS), as well as sera from individuals infected with the B.1.1.7 variant to  
31 compare cross-neutralizing activity profiles. We show that neutralizing antibodies with cross-  
32 neutralizing activity can be detected from wave 1 up to 10 months POS. Although  
33 neutralization of B.1.1.7 and B.1.351 is lower, the difference in neutralization potency  
34 decreases at later timepoints suggesting continued antibody maturation and improved  
35 tolerance to Spike mutations. Interestingly, we found that B.1.1.7 infection also generates a  
36 cross-neutralizing antibody response, which, although still less potent against B.1.351, can  
37 neutralize parental wave 1 virus to a similar degree as B.1.1.7. These findings have  
38 implications for the optimization of vaccines that protect against newly emerging viral  
39 variants.

40

41

42 **Introduction:**

43 Neutralizing antibodies against the Spike glycoprotein of severe acute respiratory  
44 syndrome coronavirus 2 (SARS-CoV-2) are important in protection from re-infection and/or  
45 severe disease.<sup>1-6</sup> Vaccines that protect against COVID-19 have been rapidly developed,  
46 and an important component of these vaccines is the elicitation of neutralizing antibodies  
47 that bind the SARS-CoV-2 Spike protein, in particular the receptor binding domain (RBD). A  
48 major challenge in controlling the COVID-19 pandemic will be elicitation of a durable  
49 neutralizing antibody response that also provides protection against SARS-CoV-2 emerging  
50 variants. Whilst the kinetics and correlates of the neutralizing antibody response have been  
51 extensively studied in the early phase following SARS-CoV-2 infection,<sup>7-12</sup> information on  
52 durability and long-term cross-reactivity of the antibody response against SARS-CoV-2  
53 following infection and/or vaccination is limited due to its recent emergence in the human  
54 population and large-scale COVID-19 vaccination only being initiated in December 2020.

55 We have previously studied the antibody response in SARS-CoV-2 infected  
56 healthcare workers and hospitalized individuals in the first 3 months following infection using  
57 longitudinal samples<sup>8</sup>. We showed that the humoral immune response was typical of that  
58 following an acute viral infection where the sera neutralizing activity peaked around 3-5  
59 weeks post onset of symptoms (POS) and then declined as the short-lived antibody-  
60 secreting cells die.<sup>3</sup> However, it remained to be seen whether the neutralizing antibody  
61 response would continue to decline after the first 3 months POS or reach a steady state. In  
62 the absence of current long-term COVID-19 vaccine follow-up, knowledge of the longevity of  
63 the neutralizing antibody response acquired through natural infection in wave 1 of the  
64 COVID-19 pandemic at late timepoints (up to 10 months POS) may provide important  
65 indicators for the durability of vaccine induced humoral immunity.

66 SARS-CoV-2 variants encoding mutations in Spike have been identified and include  
67 B.1.1.7 (initially reported in the UK),<sup>13</sup> P.1 (first reported in Brazil) and B.1.351 (first reported  
68 in South Africa)<sup>14</sup> which have been associated with more efficient transmission.<sup>15-17</sup>  
69 Mutations of particular concern for vaccine immunity are those present in the receptor

70 binding domain (RBD) of Spike which is a dominant target for the neutralizing antibody  
71 response.<sup>18</sup> Despite B.1.1.7, P.1 and B.1.351 showing increased resistance to neutralization  
72 by convalescent and vaccinee sera collected at the peak of the antibody response,<sup>19-29</sup>  
73 cross-neutralizing activity has been observed, albeit at a lower magnitude. In contrast,  
74 complete loss of neutralization has been observed for some monoclonal antibodies targeting  
75 specific epitopes on either the *N*-terminal domain (NTD) or RBD of Spike.<sup>20,22,24,25,30</sup>  
76 Combined, these studies indicate that Spike mutations may be arising in part due to the  
77 selective pressure of neutralizing antibodies in convalescent plasma<sup>31-33</sup>. To counter such  
78 mutations and their attendant antigenic changes, vaccines using the Spike proteins from  
79 these variants of concern (VOCs) are under investigation.<sup>34-37</sup> Whether the variant Spikes  
80 will elicit a robust neutralizing response with superior cross-neutralizing activity against  
81 parental strains and newly emerging variants has not been extensively studied.<sup>26,38,39</sup> Natural  
82 infection provides an important opportunity to compare the neutralizing antibody titres and  
83 cross-neutralizing activity generated from individuals exposed to different Spike variants and  
84 will give insights into how mutations in Spike impact immunogenicity, thereby informing the  
85 design of second generation vaccine candidates based on VOCs.

86 In this study we set out to investigate; i) the longevity of the neutralizing and cross-  
87 neutralizing antibody response against viral variants from wave 1 infections up to 10 months  
88 POS, ii) the immunogenicity of the B.1.1.7 Spike in natural infection, and iii) cross-reactivity  
89 of sera following B.1.1.7 infection. We collected sera between 145-305 days POS from  
90 individuals infected in wave 1 that were in our original hospitalized patient and healthcare  
91 worker cohorts, as well as sera from individuals with a confirmed B.1.1.7 infection between  
92 6-73 days POS. Following the initial decline phase, neutralization titres reached a steady  
93 state and could be detected in the majority of sera collected up to 10 months POS. We  
94 observed cross-neutralization of wild-type (Wuhan strain, WT), B.1.1.7, P.1 and B.1.351  
95 pseudotyped viral particles for both wave 1 and B.1.1.7 sera. The B.1.351 variant showed  
96 the greatest reduction in neutralization sensitivity although the fold change in neutralization  
97 compared to WT diminished at later times POS. Importantly, B.1.1.7 infection generated

98 neutralizing antibody titres against B.1.1.7 and WT virus that were more similar to each other  
99 than was observed for wave 1 sera, indicating maintained efficacy against previously  
100 circulating strains. Overall, these findings provide important insights into long-term immunity  
101 to SARS-CoV-2 and have implications for optimization of vaccines that protect against newly  
102 emerging viral variants.

103

## 104 **Results:**

### 105 **IgG to Spike persist for up to 10 months post onset of symptoms**

106 Our initial study measured antibody responses in sera up to 3 months POS in  
107 hospitalized patients and healthcare workers experiencing a range of COVID-19 severity,  
108 from asymptomatic infection to requiring ECMO.<sup>8</sup> Additional serum samples were collected  
109 from a subset of these individuals at time points >100 days POS when they returned to  
110 hospital as part of their routine clinical care, as well as from HCW still working at St Thomas'  
111 Hospital. No participants had received the COVID-19 vaccine at serum collection. In total, 64  
112 sera were collected from 38 individuals, including 16 sera collected between 145-175 days  
113 POS (TP3), 29 collected between 180-217 days (TP4), and 19 collected between 257-305  
114 days POS (TP5). We first determined the presence of IgM and IgG against Spike, RBD and  
115 N in patient sera collected at >100 days POS (**Figure 1A-F**). OD values were measured for  
116 sera diluted at 1:50. Although the IgM response decreased to low levels against S, RBD and  
117 N at later timepoints, IgM was still detected against all three antigens in some individuals.  
118 The IgG response also decreased over time to some extent for most individuals but  
119 remained detectable at timepoints up to ~300 days POS. Those with IgG OD values near to  
120 baseline spanned across all severity groups.

121 We previously used pre-COVID-19 control sera to set a threshold OD value of 4-fold  
122 above background as a cut-off for SARS-CoV-2 seropositivity.<sup>40</sup> Using this cut-off, 5/45  
123 (11.1%) and 3/19 (6.7%) of individuals had IgG below the cut-off against all three antigens  
124 (S, RBD and N) between TP3+4 and TP5, respectively. The lowest seroreactivity was  
125 observed against RBD at timepoints >145 days POS. IgG to N has been used as an

126 indicator of previous SARS-CoV-2 infection when studying COVID-19 vaccine  
127 responses.<sup>41,42</sup> However, at >145 days POS, 17/64 (26.6%) of sera had an OD value against  
128 N that was below this threshold and suggests a complementary or alternative SARS-CoV-2  
129 antigen is needed to improve the determination of previous virus exposure in the context of  
130 vaccination for individuals infected >6 months previously.

131

### 132 **Neutralizing antibody responses are maintained up 10 months post onset of** 133 **symptoms**

134 The longevity of the neutralizing activity in patient sera was measured using HIV-1  
135 based virus particles pseudotyped with SARS-CoV-2 Wuhan Spike (referred to as wild-type,  
136 WT) (**Figure 1G and Figure S1A**). Our previous study had shown a decline in neutralizing  
137 antibody titre in the first 3 months following SARS-CoV-2 infection but whether the titre  
138 would reach a steady level was not determined. The neutralization potency of matched  
139 longitudinal sera collected at timepoints up to 305 days POS revealed that the rate of decline  
140 in neutralization activity slowed in the subsequent 4–7-month period and neutralizing activity  
141 could readily be detected in 18/19 of sera tested at TP5 with a geometric mean titre (GMT)  
142 of 640. ELISA OD values for S IgG, RBD IgG and N IgG correlated well with ID<sub>50</sub> of  
143 neutralization (**Figure S1B**). A cross-sectional analysis of all the wave 1 sera showed the  
144 GMT at TP3, TP4, and TP5 decreased from 1,199 to 635 and 640, respectively. The  
145 percentage of donors displaying potent neutralization (ID<sub>50</sub> >2,000) was 48.2% at peak  
146 neutralization (as previously determined in Seow et al<sup>8</sup>) and this decreased to 27.8 %, 13.8%  
147 and 15.8 % at TP3, TP4 and TP5, respectively (**Figure S1C**).

148 We had previously observed that individuals experiencing the most severe disease  
149 had higher peak neutralization titres.<sup>8</sup> In concordance with this, we observed higher mean  
150 peak ID<sub>50</sub> values for those with most severe disease, as well as higher titres at TP3, TP4  
151 and TP5, although this trend was not always statistically significant (**Figure 1H**). A wider  
152 heterogeneity in the magnitude of the neutralizing antibody response in the 0-3 severity  
153 group was seen at all time points studied compared to the 4-5 severity group.

154 Overall, neutralizing antibody response following SARS-CoV-2 infection can persist  
155 for as long as 10 months POS.

156

157 **Sera from individuals infected during UK wave 1 shows cross-neutralizing activity**  
158 **against SARS-CoV-2 VOCs**

159 Initially, longitudinal sera collected from 14 individuals between days 6 and 305 POS  
160 were used to compare the magnitude and kinetics of neutralizing activity against the SARS-  
161 CoV-2 variants; B.1.1.7, P.1 and B.1.351 (**Figure 2A**). The kinetics of neutralizing activity in  
162 sera were similar against all four variants and a peak in neutralization was observed around  
163 3-5 weeks POS followed by decline to a steady level of neutralization (**Figure 2B**).

164 Having observed similar kinetics in the neutralization of VOCs, we focused further on  
165 the extent of cross-neutralizing activity of wave 1 sera collected at later time-points (145-305  
166 days POS). Neutralization titres ( $ID_{50}$ ) against the four variants were measured ( $n = 66$ ) and  
167 the fold change in  $ID_{50}$  compared to wild-type for each variant was compared within five time  
168 windows; acute (20-40 days POS), TP2 (55-100 days POS), TP3, TP4 and TP5 (**Figure**  
169 **2C**). Neutralization potency against the P.1 variant was most similar to neutralization  
170 potency against wild-type virus at all five time-points, with an average reduction in  $ID_{50}$   
171 ranging from 1.2-1.3 fold (**Figure 2D**). In contrast, and similar to previous reports,<sup>19-27</sup> both  
172 B.1.1.7 and B.1.351 were more resistant to neutralization at all time points, with the greatest  
173 decrease in neutralization observed for B.1.351. At later timepoints, the mean fold change in  
174 neutralization  $ID_{50}$  for both the B.1.1.7 and B.1.351 variants compared to wild-type  $ID_{50}$  was  
175 decreased in magnitude (**Figure 2D**), suggesting continued antibody maturation and  
176 improved tolerance to Spike mutations. For example, the average fold reduction in  $ID_{50}$   
177 against B.1.351 was 8.9-fold in the acute phase and this decreased to 2.9-fold at TP5.  
178 Individuals experiencing more severe COVID-19 (severity 4-5) consistently showed higher  
179 neutralization titres against the VOCs compared to those experiencing milder disease  
180 (severity 0-3) (**Figure 2E**).

181 Overall, wave 1 sera showed neutralizing activity against P.1, B.1.1.7 and B.1.351,  
182 albeit at a lower potency for B.1.1.7 and B.1.351.

183

184 **Sera from individuals infected with the B.1.1.7 variant retain neutralizing activity**  
185 **against early variants**

186 During the UK second wave of COVID-19 in December 2020 – February 2021, the  
187 predominant variant infecting patients at St Thomas Hospital in London was B.1.1.7. Whole  
188 genome sequencing was used to confirm infection with this lineage and corresponding sera  
189 samples (n = 81) were collected from 39 individuals between 4- and 79- days POS at  
190 multiple time-points where possible. Homologous neutralization and cross-neutralizing  
191 activity were measured against wild-type, P.1 and B.1.351 pseudotyped particles (**Figure 3**  
192 **and Figure S2**).

193 Sera from individuals infected with B.1.1.7 showed potent homologous neutralization  
194 (**Figure 3A**). Analysis of both serially collected samples (**Figure 3B**) and cross-sectional  
195 samples (**Figure 3A**) showed that the neutralization of the B.1.1.7 variant followed a similar  
196 kinetics with highest neutralization titres being detected around 3-5 weeks POS. For sera  
197 collected near the peak of the antibody response (21-35 days POS), more potent  
198 homologous neutralization was observed for wave 1 than B.1.1.7 sera (**Figure 3C**), i.e. a  
199 higher GMT ID<sub>50</sub> was observed for wave 1 sera against WT pseudotyped particles compared  
200 to B.1.1.7 sera against B.1.1.7 pseudotyped particles. This may be indicative of a higher  
201 immunogenicity of the WT Spike compared to the B.1.1.7 Spike, or of increased  
202 administration of immunosuppressive drugs, e.g. Dexamethasone during the 2<sup>nd</sup> wave of  
203 COVID-19 in the UK.

204 The majority of B.1.1.7 sera showed cross-neutralizing activity against the other  
205 VOCs (**Figure S2C**). Similar to wave 1 sera, the lowest cross-neutralization was observed  
206 against B.1.351 which exhibited an average 5.7-fold reduction in neutralizing activity  
207 compared to neutralization against B.1.1.7 across all samples studied. Neutralization of P.1  
208 and WT were reduced by an average 1.2- and 1.7-fold compared the B.1.1.7. To enable a



209 fair comparison of cross-neutralizing activity generated by infection with WT or B.1.1.7 virus,  
210 neutralization potency against the four viruses was compared for all sera collected between  
211 days 10 – 60 POS (**Figure 3D**). Both B.1.1.7 sera (**Figure 3D**) and wave 1 sera (**Figure 3E**)  
212 showed a reduction in neutralization of B.1.351 compared to homologous neutralization of  
213 WT and B.1.1.7 pseudotypes (average 5.9- and 8.3-fold, respectively). Neutralization of P.1  
214 by either wave 1 or B.1.1.7 sera was largely unchanged (1.3- and 1.2-fold changes,  
215 respectively). However, in contrast to convalescent sera from wave 1 that had an average  
216 3.3-fold reduction in B.1.1.7 neutralization, there was only an average 1.7-fold reduction in  
217 WT neutralization by B.1.1.7 sera suggesting that neutralization is retained against earlier  
218 lineage variants if infected with B.1.1.7.

219 As we had previously observed a correlate between disease severity and  
220 neutralization titre for wave 1 sera (**Figure 2E**), we similarly compared the geometric mean  
221 titres for those with 0-3 and 4-5 disease severity for all B.1.1.7 serum samples. In contrast to  
222 wave 1 sera, the sera from B.1.1.7 infected individuals experiencing 4-5 disease severity did  
223 not display such an enhanced neutralization potency compared to the less severe group  
224 which may also reflect the increased administration of immunosuppressive drugs during  
225 treatment (**Figure 3F**).

226 Overall, sera from individuals infected with the B.1.1.7 variant displayed potent cross-  
227 neutralizing activity.

228

### 229 **Sera from individuals infected with B.1.351 displays potent homologous** 230 **neutralization**

231 Lastly, sera were collected from three individuals receiving treatment for COVID-19  
232 at St Thomas' hospital who were confirmed to have been infected with the B.1.351 variant.  
233 All experienced severity 4 illness. Neutralization against the four variants was measured.  
234 Robust neutralization of B.1.351 was observed. Although only a very small sample size, in  
235 contrast to wave 1 and B.1.1.7 sera, neutralization of B.1.351 by these sera appeared more  
236 comparable to the other three variants (**Figure 3G**).

237

## 238 **Discussion**

239           With the recent entry of SARS-CoV-2 into the human population, there is limited  
240 information on the longevity of the antibody response following natural infection or COVID-  
241 19 vaccination. Initial concerns were that the SARS-CoV-2 antibody response might mimic  
242 that of other human endemic coronaviruses, such as 229E, where antibody responses are  
243 short-lived and re-infections occur.<sup>43,44</sup> However, the data presented here supports other  
244 recent studies<sup>9,45-52</sup> showing that although neutralizing antibody titres decline from the initial  
245 peak response, robust neutralizing activity can still be detected in a large proportion of  
246 convalescent sera at up to 10 months POS. As IgM has been shown to facilitate  
247 neutralization,<sup>8,53</sup> the initial decline in neutralization is likely in part due to the reduction in  
248 circulating serum IgM observed, as well as the death of short-lived antibody-secreting cells,  
249 with the sustained neutralizing activity therefore arising from long-lived plasma cells  
250 producing spike-reactive IgG.<sup>3,51,54</sup> We observed a more notable decline in IgG to N  
251 compared to IgG to Spike which has also been observed by others<sup>51</sup> and is particularly  
252 relevant when considering using IgG to N to determine prior SARS-CoV-2 infection in  
253 COVID-19 vaccination studies. Further assessment of the longevity of the neutralizing  
254 antibody response arising from SARS-CoV-2 natural infection will become increasingly  
255 difficult as more of the global population receive a COVID-19 vaccine.

256           Although sustained neutralization against the infecting SARS-CoV-2 variant is  
257 important, efficacious cross-neutralizing activity is essential for long-term protection against  
258 newly emerging variants. As RBD has been identified as a major target for the neutralizing  
259 antibody response to SARS-CoV-2, mutations K417T/N, E484K and N501Y are of particular  
260 concern for immune evasion and have been shown to lead to resistance to some RBD  
261 specific mAbs.<sup>25,55-58</sup> Additionally, mutations in NTD can also lead to neutralization resistance  
262 against NTD-specific mAbs.<sup>20,25,59</sup> In this present study, the largest decrease in neutralization  
263 potency for both wave 1 (overall average 4.8-fold) and B.1.1.7 sera (overall average 5.7-  
264 fold) was observed against B.1.351 which encodes RBD mutations K417N, E484K and

265 N501Y. Despite P.1 encoding similar RBD mutations K417T, E484K and N501Y, only a very  
266 minor decrease in neutralization potency was observed. As these two VOCs also encode a  
267 different pattern of NTD and S2 mutations, these data indicate that the RBD is not the only  
268 antigenic region responsible for reduced neutralization potency and suggests that  
269 assessment of mutational profiles throughout Spike will be important when considering  
270 immune evasion by emerging viral variants.<sup>24</sup>

271 Despite the reduction in neutralization potency seen in wave 1 sera against B.1.1.7  
272 and B.1.351, GMT of 3,331 and 1,303 (**Figures 2C and S2C**), respectively, were still  
273 observed at the neutralization peak, and neutralization ( $ID_{50} >25$ ) was detected in 17/19 and  
274 18/19 of individuals at 257-305 days against B.1.1.7 and B.1.351. These data highlight how  
275 the polyclonal nature of convalescent sera enables antiviral functionality against mutant  
276 Spikes present in emerging viral variants. Whether the neutralizing antibody titres reported  
277 here will be sufficient to protect from infection and/or severe disease is not fully understood.<sup>3-</sup>  
278 <sup>6,60</sup> Several studies have reported a lower vaccine efficacy in locations where B.1.351 is  
279 prevalent<sup>61,62</sup> whereas protection against B.1.1.7 infection has been reported in Israel  
280 following vaccination with BNT162b2<sup>63</sup> and following AZD1222 in the UK.<sup>64</sup> Interestingly, the  
281 differential neutralization of B.1.351 and B.1.1.7 compared to WT virus decreased at later  
282 timepoints for wave 1 sera, suggesting that antibodies present at later timepoints are better  
283 able to tolerate Spike mutations. Indeed, a study by Gaebler *et al* showed that SARS-CoV-2  
284 monoclonal antibodies isolated 6-months POS had more somatic hypermutation and  
285 displayed a greater resistance to RBD mutations.<sup>55</sup> These findings suggest that COVID-19  
286 vaccine boosting may further increase neutralization breadth and protection against newly  
287 emerging SARS-CoV-2 VOCs.

288 Spikes from VOCs are being investigated as second-generation vaccine candidates  
289 to tackle the challenges associated with protection against SARS-CoV-2 emerging  
290 variants<sup>34-37</sup> and therefore, studying the immune response to Spike variants in natural  
291 infection can provide insight into differential Spike immunogenicity. We show that infection  
292 with B.1.1.7 elicits a robust neutralizing antibody response against B.1.1.7, P.1 and WT

293 variants. For the majority of donors, the ID<sub>50</sub>s against B.1.1.7 and WT were very similar  
294 indicating that neutralizing antibodies arising from infection with B.1.1.7 are able to maintain  
295 efficacy against previously dominant SARS-CoV-2 variants. These findings contrast with  
296 Faulkner *et al* who observed a decreased level of cross-neutralization in B.1.1.7 infected  
297 individuals.<sup>38</sup> However, Faulkner *et al* used sera collected at around 11 days POS and, as  
298 discussed above, cross-neutralizing activity likely develops over time. Here we show that,  
299 similar to wave 1 sera, neutralization of B.1.351 by B.1.1.7 sera was reduced compared  
300 neutralization of B.1.1.7 and suggests the shared N501Y mutation is not sufficient to  
301 overcome the B.1.351 neutralization resistance, an independent SARS-CoV-2 lineage. A  
302 study by Moyo-Gwete *et al* demonstrated that individuals infected with B.1.351 elicited  
303 potent neutralizing antibodies against B.1.351 and P.1 but reduced titres against Wuhan-  
304 D614G variant.<sup>39</sup> Cele *et al* showed that B.1.351 infection generated better cross-  
305 neutralizing activity against earlier viral variants.<sup>26</sup> Although a small sample size, our data  
306 broadly support these observations and further demonstrate that B.1.351 infection elicits a  
307 robust homologous neutralizing antibody response that also cross-neutralizes other VOCs.

308 Previous studies of wave 1 sera comparing antibody responses in individuals  
309 experiencing different disease severities has shown that higher neutralization titres are  
310 typically observed in those experiencing more severe disease.<sup>8,21,65-67</sup> Here we further show  
311 that the difference in neutralization potency decreases at later timepoints. Indeed, Vanshylla  
312 *et al* observed a more rapid initial decline in neutralizing antibody titres in those who  
313 experience severe disease.<sup>50</sup> A similar analysis conducted with sera from B.1.1.7 infected  
314 individuals revealed more similar neutralizing antibody responses between the two severity  
315 groups. Whether this is related to improved disease management and increased use of  
316 immunosuppressive drugs during the UK second wave infections or is intrinsic to the B.1.1.7  
317 Spike would need to be investigated further.

318 In summary, using convalescent sera from individuals infected in wave 1 or  
319 individuals infected with B.1.1.7, we show that cross-neutralizing antibodies are detected up  
320 to 10 months POS in some individuals and that infection with B.1.1.7 generates a cross-

321 neutralizing antibody response that is effective against the parental virus. These findings  
322 have implications for optimization of COVID-19 vaccines effective at eliciting a cross-  
323 neutralizing antibody response that protects against SARS-CoV-2 viral variants.  
324

325 **Methods:**

326 **Patient samples.** Collection of surplus serum samples was approved by South Central REC  
327 20/SC/0310. SARS-CoV-2 cases were diagnosed by RT-PCR of respiratory samples at St  
328 Thomas' Hospital, London. 894 serum samples from 585 individuals were saved between 04  
329 January 2020 and 12 March 2021. Samples obtained ranged from 8 days prior up to 319  
330 days POS. Cases were linked to corresponding genome sequencing of viral isolates from  
331 nose and throat swabs. Some sera were previously studied in Seow *et al*<sup>8</sup> as stated in the  
332 manuscript.

333

334 **Plasmids.** The wild-type<sup>8</sup> and B.1.1.7<sup>20,21</sup> Spike plasmids were described previously. B.1.1.7  
335 mutations introduced were  $\Delta$ H69/V70,  $\Delta$ Y144, N501Y, A570D, D614G, P681H, T716I,  
336 S982A, D1118H. Spikes encoding the variants B.1.351 and P.1 were synthesized (Genewiz,  
337 USA) and cloned into pcDNA3.1. B.1.351 mutations introduced were L18F, D80A, D215G,  
338 Delta242-244, R246I, K417N, E484K, N501Y, D614G, A701V. P.1 mutations introduced  
339 were L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I,  
340 V1176F.

341

342 **COVID-19 severity classification.** The score, ranging from 0 to 5, was devised  
343 to mitigate underestimating disease severity in patients not for escalation above level one  
344 (ward-based) care. Patients diagnosed with COVID-19 were classified as follows: (0)  
345 Asymptomatic or no requirement for supplemental oxygen; (1) Requirement for  
346 supplemental oxygen (fraction of inspired oxygen ( $FIO_2$ ) < 0.4) for at least 12 h; (2)  
347 Requirement for supplemental oxygen ( $FIO_2 \geq 0.4$ ) for at least 12 h; (3) Requirement for  
348 non-invasive ventilation/continuous positive airway not a candidate for escalation above  
349 level one (ward-based) care; (4) Requirement for intubation and mechanical ventilation or  
350 supplemental oxygen ( $FIO_2 > 0.8$ ) and peripheral oxygen saturations <90% (with no history  
351 of type 2 respiratory failure (T2RF)) or <85% (with known T2RF) for at least 12 h; (5)  
352 Requirement for ECMO.

353

354 **Viral sequencing.** Whole genome sequencing of residual nose-and-throat swab from  
355 SARS-CoV-2 cases was performed using GridION (Oxford Nanopore Technology), using  
356 version 3 of the ARTIC protocol and bioinformatics pipeline.<sup>68</sup> From November 2020 all  
357 samples from inpatients were assessed for sequencing. Samples were selected for  
358 sequencing if the corrected CT value was 32 or below, or the Hologic Aptima assay was  
359 above 1000 RLU, and if there was sufficient residual sample. Sequencing was performed  
360 under COG-UK ethical approval. Lineage determination was performed using updated  
361 versions of pangolin 2.0.<sup>69</sup> Samples were regarded as successfully sequenced if over 50%  
362 of the genome was recovered and if lineage assignment by pangolin was given with at least  
363 50% confidence.

364

365 **ELISA binding to N, S and RBD.** ELISAs were carried out as previously described.<sup>8,40</sup> All  
366 sera were heat inactivated at 56 °C for 30 min before use. High-binding ELISA plates  
367 (Corning, 3690) were coated with antigen (N protein, S glycoprotein or RBD) at 3 µg/mL (25  
368 µl per well) in phosphate-buffered serum (PBS), either overnight at 4 °C or for 2 h at 37 °C.  
369 Wells were washed with PBS-T (PBS with 0.05% Tween-20) and then blocked with 100 µl of  
370 5% milk in PBS-T for 1 h at room temperature. The wells were emptied, and serum diluted at  
371 1:50 in milk was added and incubated for 2 h at room temperature. Wells were washed with  
372 PBS-T. Secondary antibody was added and incubated for 1 h at room temperature. IgM was  
373 detected using goat-anti-human-IgM-HRP (horseradish peroxidase) (1:1,000) (Sigma,  
374 catalogue no. A6907) and IgG was detected using goat-anti-human-Fc-AP (alkaline  
375 phosphatase) (1:1,000) (Jackson, catalogue no. 109-055-098). Wells were washed with  
376 PBS-T and either AP substrate (Sigma) was added and read at 405 nm (AP) or one-step  
377 3,3',5,5'-tetramethylbenzidine (TMB) substrate (Thermo Fisher Scientific) was added and  
378 quenched with 0.5 M H<sub>2</sub>SO<sub>4</sub> before reading at 450 nm (HRP). Control reagents included  
379 CR3009 (2 µg/mL), CR3022 (0.2 µg/mL), negative control plasma (1:25 dilution), positive

380 control plasma (1:50) and blank wells. ELISA measurements were performed in duplicate  
381 and the mean of the two values was used.

382

383 **SARS-CoV-2 pseudotyped virus particle preparation.** Pseudotyped HIV virus  
384 incorporating the SARS-CoV-2 Spike protein (either wild-type, B.1.1.7, P.1, B.1.351) was  
385 produced in a 10 cm dish seeded the day prior with  $5 \times 10^6$  HEK293T/17 cells in 10 ml of  
386 complete Dulbecco's Modified Eagle's Medium (DMEM-C, 10% FBS and 1% Pen/Strep)  
387 containing 10% (vol/vol) foetal bovine serum (FBS), 100 IU/ml penicillin and 100 µg/ml  
388 streptomycin. Cells were transfected using 90 µg of PEI-Max (1 mg/mL, Polysciences) with:  
389 15µg of HIV-luciferase plasmid, 10 µg of HIV 8.91 gag/pol plasmid and 5 µg of SARS-CoV-2  
390 spike protein plasmid.<sup>70,71</sup> The supernatant was harvested 72 hours post-transfection.  
391 Pseudotyped virus particles was filtered through a 0.45µm filter and stored at -80°C until  
392 required.

393

394 **Neutralization assay with SARS-CoV-2 pseudotyped virus.** Serial dilutions of serum  
395 samples (heat inactivated at 56°C for 30mins) were prepared with DMEM media (25uL)  
396 (10% FBS and 1% Pen/Strep) and incubated with pseudotype virus (25uL) for 1-hour at  
397 37°C in half-area 96-well plates. Next, Hela cells stably expressing the ACE2 receptor were  
398 added (10,000 cells/25µL per well) and the plates were left for 72 hours. Infection level was  
399 assessed in lysed cells with the Bright-Glo luciferase kit (Promega), using a Victor™ X3  
400 multilabel reader (Perkin Elmer). Each serum sample was run in duplicate and was  
401 measured against the four SARS-CoV-2 variants within the same experiment using the  
402 same dilution series.

403

404



405 **Acknowledgments:**

406 This work was funded by; King's Together Rapid COVID-19 Call awards to MHM, KJD and  
407 SJDN, MRC Discovery Award MC/PC/15068 to SJDN, KJD and MHM, Fondation Dormeur,  
408 Vaduz for funding equipment to KJD, Huo Family Foundation Award to MHM, KJD, MSH  
409 and SJDN, MRC Genotype-to-Phenotype UK National Virology Consortium (MR/W005611/1  
410 to MHM, KJD and SJDN), MRC Programme Grant (MR/S023747/1 to MHM), Wellcome  
411 Trust Investigator Award 106223/Z/14/Z to MHM, NIAID Awards AI150472 and AI076119 to  
412 MHM. MSH is funded by the National Institute for Health Research Clinician Scientist Award  
413 (CS-2016-16-011). The views expressed in this publication are those of the author(s) and  
414 not necessarily those of the NHS, the National Institute for Health Research or the  
415 Department of Health and Social Care. CG, SH and HW were supported by the MRC-KCL  
416 Doctoral Training Partnership in Biomedical Sciences (MR/N013700/1). SA was supported  
417 by an MRC-KCL Doctoral Training Partnership in Biomedical Sciences industrial  
418 Collaborative Award in Science & Engineering (iCASE) in partnership with Orchard  
419 Therapeutics (MR/R015643/1). NA is funded by the Wellcome Trust PhD program Cell  
420 therapies and regenerative medicine (108874/Z/15/Z). This work was supported by the  
421 Department of Health via a National Institute for Health Research comprehensive  
422 Biomedical Research Centre award to Guy's and St. Thomas' NHS Foundation Trust in  
423 partnership with King's College London and King's College Hospital NHS Foundation Trust.  
424 This study is part of the EDCTP2 programme supported by the European Union (grant  
425 number RIA2020EF-3008 COVAB). The views and opinions of authors expressed herein do  
426 not necessarily state or reflect those of EDCTP.


427

428 Thank you to Florian Krammer for provision of the RBD expression plasmid, Philip Brouwer,  
429 Marit van Gils and Rogier Sanders (University of Amsterdam) for the Spike protein construct,  
430 Leo James and Jakub Luptak for the N protein, and James Voss and Deli Huang for  
431 providing the Hela-ACE2 cells.

432

433 **Figures:**

434 **Figure 1: Serum Spike IgG binding and neutralizing activity is sustained up to 305**  
435 **days POS.** ELISA was used to assess the binding of A) IgM to Spike, B) IgM to RBD, C)  
436 IgM to N, D) IgG to S, E) IgG to RBD and F) IgG to N. Sera was diluted to 1:50 and samples  
437 were run in duplicate. The vertical dotted line indicates the time period that was studied in  
438 our original analysis of this cohort.<sup>8</sup> Each line represents one individual, and they are colour  
439 coded as follows: red – severity 4-5, black – severity 0-3 and green – healthcare workers. G)  
440 Neutralization (ID<sub>50</sub>) measured against HIV-1 pseudotyped virus particles expressing the  
441 Wuhan Spike (wild-type, WT). The vertical dotted line indicates the latest timepoint studied  
442 in our original analysis of this cohort.<sup>8</sup> H) Comparison of the mean ID<sub>50</sub> between individuals  
443 experiencing 0-3 and 4-5 disease severity at different times post onset of symptoms (POS)  
444 and for the highest neutralization titre measured (Peak). Severity 0-3 is shown in black and  
445 severity 4-5 is shown in red. *p*-values were calculated using a Mann–Whitney two-sided test  
446 *U*-test. ns, not significant. The line represents the geometric mean ID<sub>50</sub> for each group.




447

448




450 **Figure 2: Sera from Wave 1 shows cross-neutralization of SARS-CoV-2 variants of**  
451 **concern.** A) Schematic showing the position of Spike mutations in B.1.1.7, P.1 and B.1.351.  
452 The major Spike domains are indicated. B) Longitudinal neutralization by wave 1 sera  
453 against WT, B.1.1.7, P.1 and B.1.351. Neutralization is shown for 14 individuals. C)  
454 Neutralization of sera collected within five different time periods against the four SARS-CoV-  
455 2 variants. Geometric mean titres (GMT) against each virus are shown on each panel. Each  
456 line represents one individual, and each individual is sampled  $\leq 1$  at each timepoint. The  
457 dotted lines represent the neutralization cut-offs used to determine no, low, medium, high  
458 and potent neutralization (See **Figures S1C**). Red line represents the geometric mean titre  
459 against that virus. D) Fold change in neutralization compared to WT pseudovirus at the five  
460 timepoints. Black lines represent the average fold change. E) Comparison of the geometric  
461 mean titre between those with 0-3 (Black) and 4-5 (red) disease severity for the four  
462 variants. All sera collected up to 305 days POS are included in this analysis ( $n = 107$ ).  $p$ -  
463 values were calculated using a Mann–Whitney two-sided test  $U$ -test. ns, not significant. The  
464 line represents the geometric mean  $ID_{50}$  for each group.



465

466

467 **Figure 3: Neutralizing antibody response in individuals infected with B.1.1.7.** A) Serum  
468 neutralization against B.1.1.7 at different time windows. Black line represents the geometric  
469 mean titre. B) Neutralization of B.1.1.7 pseudovirus by sequential serum samples. Each line  
470 represents samples from 1 donor across multiple timepoints. C) Comparison of homologous  
471 neutralization (i.e. neutralization of WT pseudovirus by wave 1 sera and neutralization of  
472 B.1.1.7 pseudovirus by sera from B.1.1.7 infected individuals) at peak neutralization (21-35  
473 days POS). Line represents the geometric mean titre. *p*-values were calculated using a  
474 Mann–Whitney two-sided test *U*-test. D) Cross-neutralizing activity of sera collected between  
475 days 10-60 POS from individuals infected with B.1.1.7 against 4 SARS-CoV-2 variants (*n* =  
476 74). Each line represents a serum sample. Red line represents the geometric mean titre  
477 against that virus. E) Cross-neutralizing activity of sera collected between days 10-60 POS  
478 from individuals infected in wave 1 against 4 SARS-CoV-2 variants (*n* = 35). Each line  
479 represents a serum sample. Red line represents the geometric mean titre against that virus.  
480 F) Comparison of the neutralization potency of B.1.1.7 sera against SARS-CoV-2 variants  
481 between individuals experiencing disease severity 0-3 and 4-5. The black lines represent the  
482 geometric mean titres. *p*-values were calculated using a Mann–Whitney two-sided test *U*-  
483 test. ns, not significant. G) Cross-neutralizing activity of sera collected from three individuals  
484 infected with B.1.351. Sera were collected at two time points from two of these individuals  
485 (between 26-52 days POS). Red line represents the geometric mean titre against that virus.



486


487

488

489 **Supplementary Figures:**

490 **Figure S1: Neutralizing antibodies persist for up to 10 months post onset of**  
491 **symptoms.** A) ID<sub>50</sub> of neutralization for all wave 1 sera included in Figure 1G. B) Correlation  
492 between ID<sub>50</sub> (measured against pseudovirus) and either optimal density of IgG binding to S,  
493 RBD or N. ( $r^2 = 0.6942$ ), RBD ( $r^2 = 0.6250$  and N protein ( $r^2 = 0.3861$ ) (Spearman's  
494 correlation,  $r$ ; a linear regression was used to calculate the goodness of fit,  $r^2$ ). C)  
495 Percentage of individuals in each time window with undetectable (ID<sub>50</sub> <25), low (ID<sub>50</sub> 25 –  
496 200), medium (ID<sub>50</sub> 201 – 500), high (ID<sub>50</sub> 501 – 2,000) or potent (ID<sub>50</sub> 2,000+) neutralizing  
497 antibody titres. The peak neutralization time point (n = ) includes hospitalized patients and  
498 healthcare workers reported in Seow *et al*,<sup>8</sup> as well as 14 additional donors reported in this  
499 study. The time point from the longitudinal samples with the peak ID<sub>50</sub> was used in “peak”.  
500 TP3, TP4 and TP5 include serum samples collected between 145-175, 180-217 and 257-  
501 305 days POS.






502

503 **Figure S2: Cross-neutralizing antibody response in individuals infected with B.1.1.7.**

504 A) Serum neutralization against WT, P.1 and B.1.351 at different time windows. Black line  
 505 represents the geometric mean titre. B) Neutralization of WT, P.1 and B.1.351 pseudovirus  
 506 by sequential serum samples. Each line represents samples from 1 donor across multiple  
 507 timepoints. C) Cross-neutralizing activity of sera from individuals infected with B.1.1.7  
 508 against 4 SARS-CoV-2 variants (n = 83). Each line represents a serum sample. Red line  
 509 represents the geometric mean titre against that virus.



510

511

512

513 **References:**

- 514 1 van Doremalen, N. *et al.* ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2  
515 pneumonia in rhesus macaques. *Nature* **586**, 578-582, doi:10.1038/s41586-020-  
516 2608-y (2020).
- 517 2 Addetia, A. *et al.* Neutralizing Antibodies Correlate with Protection from SARS-CoV-2  
518 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. *J Clin*  
519 *Microbiol* **58**, doi:10.1128/JCM.02107-20 (2020).
- 520 3 Cromer, D. *et al.* Prospects for durable immune control of SARS-CoV-2 and  
521 prevention of reinfection. *Nat Rev Immunol*, doi:10.1038/s41577-021-00550-x (2021).
- 522 4 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune  
523 protection from symptomatic SARS-CoV-2 infection. *Nat Med*, doi:10.1038/s41591-  
524 021-01377-8 (2021).
- 525 5 Chandrashekar, A. *et al.* SARS-CoV-2 infection protects against rechallenge in  
526 rhesus macaques. *Science* **369**, 812-817, doi:10.1126/science.abc4776 (2020).
- 527 6 McMahan, K. *et al.* Correlates of protection against SARS-CoV-2 in rhesus  
528 macaques. *Nature* **590**, 630-634, doi:10.1038/s41586-020-03041-6 (2021).
- 529 7 Muecksch, F. *et al.* Longitudinal analysis of serology and neutralizing antibody levels  
530 in COVID19 convalescents. *J Infect Dis*, doi:10.1093/infdis/jiaa659 (2020).
- 531 8 Seow, J. *et al.* Longitudinal observation and decline of neutralizing antibody  
532 responses in the three months following SARS-CoV-2 infection in humans. *Nat*  
533 *Microbiol* **5**, 1598-1607, doi:10.1038/s41564-020-00813-8 (2020).
- 534 9 Wajnberg, A. *et al.* Robust neutralizing antibodies to SARS-CoV-2 infection persist  
535 for months. *Science* **370**, 1227-1230, doi:10.1126/science.abd7728 (2020).
- 536 10 Beaudoin-Bussieres, G. *et al.* Decline of Humoral Responses against SARS-CoV-2  
537 Spike in Convalescent Individuals. *mBio* **11**, doi:10.1128/mBio.02590-20 (2020).
- 538 11 Crawford, K. H. D. *et al.* Dynamics of neutralizing antibody titers in the months after  
539 SARS-CoV-2 infection. *J Infect Dis*, doi:10.1093/infdis/jiaa618 (2020).
- 540 12 Carvalho, T., Krammer, F. & Iwasaki, A. The first 12 months of COVID-19: a timeline  
541 of immunological insights. *Nat Rev Immunol* **21**, 245-256, doi:10.1038/s41577-021-  
542 00522-1 (2021).
- 543 13 Rambaut, A. *et al.* Preliminary genomic characterisation of an emergent SARS-CoV-  
544 2 lineage in the UK defined by a novel set of spike mutations. . (2020).
- 545 14 Tegally, H. *et al.* Sixteen novel lineages of SARS-CoV-2 in South Africa. *Nat Med* **27**,  
546 440-446, doi:10.1038/s41591-021-01255-3 (2021).
- 547 15 Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage  
548 B.1.1.7 in England. *Science* **372**, doi:10.1126/science.abg3055 (2021).
- 549 16 Brown, J. C. & al, e. Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC  
550 202012/01) is not accounted for by a replicative advantage in primary airway cells  
551 or antibody escape. *bioRxiv*, doi:10.1101/2021.02.24.432576 (2021).
- 552 17 Volz, E. & al, e. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights  
553 from linking epidemiological and genetic data. *medRxiv*,  
554 doi:10.1101/2020.12.30.20249034 (2021).
- 555 18 Piccoli, L. *et al.* Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-  
556 2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.  
557 *Cell* **183**, 1024-1042 e1021, doi:10.1016/j.cell.2020.09.037 (2020).
- 558 19 Garcia-Beltran, W. F. *et al.* Multiple SARS-CoV-2 variants escape neutralization by  
559 vaccine-induced humoral immunity. *Cell*, doi:10.1016/j.cell.2021.03.013 (2021).
- 560 20 Graham, C. *et al.* Neutralization potency of monoclonal antibodies recognizing  
561 dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the  
562 B.1.1.7 variant. *Immunity*, doi:10.1016/j.immuni.2021.03.023 (2021).
- 563 21 Rees-Spear, C. *et al.* The effect of spike mutations on SARS-CoV-2 neutralization.  
564 *Cell Rep*, 108890, doi:10.1016/j.celrep.2021.108890 (2021).
- 565 22 Zhou, D. *et al.* Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and  
566 vaccine-induced sera. *Cell*, doi:10.1016/j.cell.2021.02.037 (2021).

- 567 23 Supasa, P. *et al.* Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by  
568 convalescent and vaccine sera. *Cell* **184**, 2201-2211 e2207,  
569 doi:10.1016/j.cell.2021.02.033 (2021).
- 570 24 Wang, P. *et al.* Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7.  
571 *Nature*, doi:10.1038/s41586-021-03398-2 (2021).
- 572 25 Wibmer, C. K. *et al.* SARS-CoV-2 501Y.V2 escapes neutralization by South African  
573 COVID-19 donor plasma. *Nat Med*, doi:10.1038/s41591-021-01285-x (2021).
- 574 26 Cele, S. *et al.* Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent  
575 plasma. *Nature* **593**, 142-146, doi:10.1038/s41586-021-03471-w (2021).
- 576 27 Chen, R. E. & al, e. Resistance of SARS-CoV-2 variants to neutralization by  
577 monoclonal and serum-derived polyclonal antibodies. *Nat Med*,  
578 doi:doi.org/10.1038/s41591-021-01294-w (2021).
- 579 28 Wang, P. *et al.* Increased resistance of SARS-CoV-2 variant P.1 to antibody  
580 neutralization. *Cell Host Microbe* **29**, 747-751 e744, doi:10.1016/j.chom.2021.04.007  
581 (2021).
- 582 29 Planas, D. *et al.* Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to  
583 neutralizing antibodies. *Nat Med* **27**, 917-924, doi:10.1038/s41591-021-01318-5  
584 (2021).
- 585 30 Collier, D. A. *et al.* Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited  
586 antibodies. *Nature*, doi:10.1038/s41586-021-03412-7 (2021).
- 587 31 Kemp, S. A. *et al.* SARS-CoV-2 evolution during treatment of chronic infection.  
588 *Nature*, doi:10.1038/s41586-021-03291-y (2021).
- 589 32 McCarthy, K. R. *et al.* Recurrent deletions in the SARS-CoV-2 spike glycoprotein  
590 drive antibody escape. *Science*, doi:10.1126/science.abf6950 (2021).
- 591 33 Harvey, W. T. *et al.* SARS-CoV-2 variants, spike mutations and immune escape. *Nat*  
592 *Rev Microbiol*, doi:10.1038/s41579-021-00573-0 (2021).
- 593 34 Su, D. Broad neutralization against SARS-CoV-2 variants induced by a modified  
594 B.1.351 protein-based COVID-19 vaccine candidate. *bioRxiv*,  
595 doi:10.1101/2021.05.16.444369 (2021).
- 596 35 Callaway, E. Rare COVID reactions might hold key to variant-proof vaccines. *Nature*  
597 **592**, 20-21, doi:10.1038/d41586-021-00722-8 (2021).
- 598 36 Ji, R. R. *et al.* BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects  
599 Transgenic hACE2 Mice against COVID-19. *Vaccines (Basel)* **9**,  
600 doi:10.3390/vaccines9040324 (2021).
- 601 37 Wu, K. *et al.* Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as  
602 primary or booster series in mice. *bioRxiv*, doi:10.1101/2021.04.13.439482 (2021).
- 603 38 Faulkner, N. & al, e. Reduced antibody cross-reactivity following infection with  
604 B.1.1.7 than with parental SARS-CoV-2 strains. *bioRxiv*,  
605 doi:10.1101/2021.03.01.433314 (2021).
- 606 39 Moyo-Gwete, T. *et al.* Cross-Reactive Neutralizing Antibody Responses Elicited by  
607 SARS-CoV-2 501Y.V2 (B.1.351). *N Engl J Med*, doi:10.1056/NEJMc2104192 (2021).
- 608 40 Pickering, S. *et al.* Comparative assessment of multiple COVID-19 serological  
609 technologies supports continued evaluation of point-of-care lateral flow assays in  
610 hospital and community healthcare settings. *PLoS Pathog* **16**, e1008817,  
611 doi:10.1371/journal.ppat.1008817 (2020).
- 612 41 Monin, L. *et al.* Safety and immunogenicity of one versus two doses of the COVID-19  
613 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective  
614 observational study. *Lancet Oncol*, doi:10.1016/S1470-2045(21)00213-8 (2021).
- 615 42 Parry, H. F. & al, e. Extended interval BNT162b2 vaccination enhances peak  
616 antibody generation in older people. *medRxiv*, doi:10.1101/2021.05.15.21257017  
617 (2021).
- 618 43 Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. The time course of the  
619 immune response to experimental coronavirus infection of man. *Epidemiol Infect*  
620 **105**, 435-446, doi:10.1017/s0950268800048019 (1990).

- 621 44 Edridge, A. W. D. *et al.* Seasonal coronavirus protective immunity is short-lasting.  
622 *Nat Med* **26**, 1691-1693, doi:10.1038/s41591-020-1083-1 (2020).
- 623 45 Wu, J. *et al.* SARS-CoV-2 infection induces sustained humoral immune responses in  
624 convalescent patients following symptomatic COVID-19. *Nat Commun* **12**, 1813,  
625 doi:10.1038/s41467-021-22034-1 (2021).
- 626 46 Yamayoshi, S. *et al.* Antibody titers against SARS-CoV-2 decline, but do not  
627 disappear for several months. *EClinicalMedicine* **32**, 100734,  
628 doi:10.1016/j.eclinm.2021.100734 (2021).
- 629 47 Dan, J. M. *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8  
630 months after infection. *Science* **371**, doi:10.1126/science.abf4063 (2021).
- 631 48 Anand, S. P. *et al.* Longitudinal analysis of humoral immunity against SARS-CoV-2  
632 Spike in convalescent individuals up to 8 months post-symptom onset. *bioRxiv*,  
633 doi:10.1101/2021.01.25.428097 (2021).
- 634 49 Wheatley, A. K. *et al.* Evolution of immune responses to SARS-CoV-2 in mild-  
635 moderate COVID-19. *Nat Commun* **12**, 1162, doi:10.1038/s41467-021-21444-5  
636 (2021).
- 637 50 Vanshylla, K. *et al.* Kinetics and correlates of the neutralizing antibody response to  
638 SARS-CoV-2 infection in humans. *Cell Host Microbe*,  
639 doi:10.1016/j.chom.2021.04.015 (2021).
- 640 51 Cohen, K. W. *et al.* Longitudinal analysis shows durable and broad immune memory  
641 after SARS-CoV-2 infection with persisting antibody responses and memory B and T  
642 cells. *medRxiv*, doi:10.1101/2021.04.19.21255739 (2021).
- 643 52 Anand, S. P. *et al.* Longitudinal analysis of humoral immunity against SARS-CoV-2  
644 Spike in convalescent individuals up to eight months post-symptom onset. *Cell Rep*  
645 *Med*, 100290, doi:10.1016/j.xcrm.2021.100290 (2021).
- 646 53 Gasser, R. *et al.* Major role of IgM in the neutralizing activity of convalescent plasma  
647 against SARS-CoV-2. *Cell Rep* **34**, 108790, doi:10.1016/j.celrep.2021.108790  
648 (2021).
- 649 54 Turner, J. S. *et al.* SARS-CoV-2 infection induces long-lived bone marrow plasma  
650 cells in humans. *Nature*, doi:10.1038/s41586-021-03647-4 (2021).
- 651 55 Gaebler, C. *et al.* Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-  
652 644, doi:10.1038/s41586-021-03207-w (2021).
- 653 56 Weisblum, Y. *et al.* Escape from neutralizing antibodies by SARS-CoV-2 spike  
654 protein variants. *Elife* **9**, doi:10.7554/eLife.61312 (2020).
- 655 57 Greaney, A. J. *et al.* Comprehensive mapping of mutations in the SARS-CoV-2  
656 receptor-binding domain that affect recognition by polyclonal human plasma  
657 antibodies. *Cell Host Microbe*, doi:10.1016/j.chom.2021.02.003 (2021).
- 658 58 Starr, T. N. *et al.* Prospective mapping of viral mutations that escape antibodies used  
659 to treat COVID-19. *Science*, doi:10.1126/science.abf9302 (2021).
- 660 59 McCallum, M. *et al.* N-terminal domain antigenic mapping reveals a site of  
661 vulnerability for SARS-CoV-2. *Cell*, doi:10.1016/j.cell.2021.03.028 (2021).
- 662 60 Fischer, R. J. *et al.* ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-  
663 CoV-2 B.1.351 and B.1.1.7 disease. *bioRxiv*, doi:10.1101/2021.03.11.435000 (2021).
- 664 61 Madhi, S. A. *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the  
665 B.1.351 Variant. *N Engl J Med*, doi:10.1056/NEJMoa2102214 (2021).
- 666 62 Shinde, V. *et al.* Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351  
667 Variant. *N Engl J Med*, doi:10.1056/NEJMoa2103055 (2021).
- 668 63 Munitz, A., Yechezkel, M., Dickstein, Y., Yamin, D. & Gerlic, M. BNT162b2  
669 Vaccination Effectively Prevents the Rapid Rise of SARS-CoV-2 Variant B.1.1.7 in  
670 high risk populations in Israel. *Cell Rep Med*, 100264,  
671 doi:10.1016/j.xcrm.2021.100264 (2021).
- 672 64 Emary, K. R. W. *et al.* Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against  
673 SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a  
674 randomised controlled trial. *Lancet* **397**, 1351-1362, doi:10.1016/S0140-  
675 6736(21)00628-0 (2021).

676 65 Guthmiller, J. J. *et al.* SARS-CoV-2 Infection Severity Is Linked to Superior Humoral  
677 Immunity against the Spike. *mBio* **12**, doi:10.1128/mBio.02940-20 (2021).  
678 66 Legros, V. *et al.* A longitudinal study of SARS-CoV-2-infected patients reveals a high  
679 correlation between neutralizing antibodies and COVID-19 severity. *Cell Mol*  
680 *Immunol*, doi:10.1038/s41423-020-00588-2 (2021).  
681 67 Zohar, T. *et al.* Compromised Humoral Functional Evolution Tracks with SARS-CoV-  
682 2 Mortality. *Cell* **183**, 1508-1519 e1512, doi:10.1016/j.cell.2020.10.052 (2020).  
683 68 ARTICnetwork, <<https://artic.network/ncov-2019>> (2021).  
684 69 O'Toole, A. *et al.* pangolin: lineage assignment in an emerging pandemic as an  
685 epidemiological tool, <<https://github.com/cov-lineages/pangolin>> (2021).  
686 70 Grehan, K., Ferrara, F. & Temperton, N. An optimised method for the production of  
687 MERS-CoV spike expressing viral pseudotypes. *MethodsX* **2**, 379-384,  
688 doi:10.1016/j.mex.2015.09.003 (2015).  
689 71 Thompson, C. P. *et al.* Detection of neutralising antibodies to SARS-CoV-2 to  
690 determine population exposure in Scottish blood donors between March and May  
691 2020. *Euro Surveill* **25**, doi:10.2807/1560-7917.ES.2020.25.42.2000685 (2020).  
692